Adial Pharmaceuticals (ADIL) announced a “positive” response from the U.S. FDA regarding its proposed in vitro bridging strategy for AD04. The FDA’s feedback follows Adial’s submission on ...

GLEN ALLEN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical ...

FDA feedback confirms Adial’s proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval ...

Adial Pharmaceuticals has a 1-year low of $0.61 and a 1-year high of $3.10. The stock’s fifty day simple moving average is $0.86 and its 200-day simple moving average is $0.98.

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

This page features the latest news about the Adial Pharma stock. Rodman & Renshaw maintains Adial stock Buy rating, $8 target Tuesday On Tuesday, Rodman & Renshaw reaffirmed their Buy rating and $ ...

The FDA agreed with Adial’s proposed 505(b)(2) bridging strategy, supporting AD04's progression to Phase 3 trials in 2025. Adial’s AD04-103 study shows bioavailability, dose proportionality ...

With FDA confirmation, Adial is commencing manufacturing of clinical supplies for Phase 3 clinical program in 2025. Secured several foundational patents, strengthening IP portfolio in support of ...